Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Key facts

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Principal Investigator

Jorge Cortes, MD

M.D. Anderson Cancer Center

Intervention

Omacetaxine mepesuccinate(drug)

Enrollment

100 target

Eligibility

18 years · All sexes

Timeline

2007 – 2013

Study locations (29)

• Teva Investigational Site 303, Los Angeles, California, United States
• Teva Investigational Site 308, Beech Grove, Indiana, United States
• Teva Investigational Site 311, Baltimore, Maryland, United States
• Teva Investigational Site 305, Buffalo, New York, United States
• Teva Investigational Site 302, The Bronx, New York, United States
• Teva Investigational Site 310, Philadelphia, Pennsylvania, United States
• Teva Investigational Site 301, Houston, Texas, United States
• Teva Investigational Site 314, Seattle, Washington, United States
• Teva Investigational Site 313, Montreal, Canada
• Teva Investigational Site 309, Toronto, Canada
• Teva Investigational Site 329, Bordeaux, France
• Teva Investigational Site 321, Le Chesnay, France
• Teva Investigational Site 322, Lille, France
• Teva Investigational Site 320, Lyon, France
• Teva Investigational Site 324, Nice, France
• +14 more locations on ClinicalTrials.gov

Collaborators

Cephalon · ChemGenex Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chronic myeloid leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07354074
  Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
  Novartis Pharmaceuticals
• RECRUITINGNCT07375355
  Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
  Novartis Pharmaceuticals
• ENROLLING BY INVITATIONNCT07383298
  Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
  Qian Jiang
• RECRUITINGPHASE2NCT06817720
  Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
  M.D. Anderson Cancer Center
• RECRUITINGNCT07061145
  A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
  Azienda USL Reggio Emilia - IRCCS
• RECRUITINGPHASE2NCT06409936
  PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
  Gruppo Italiano Malattie EMatologiche dell'Adulto
• RECRUITINGPHASE2NCT06514534
  Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
  Novartis Pharmaceuticals
• RECRUITINGPHASE1NCT06787144
  ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
  Enliven Therapeutics

See all trials for Chronic myeloid leukemia →